A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: The NEW BEACON study
Số trang: 6
Loại file: pdf
Dung lượng: 682.90 KB
Lượt xem: 8
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median progression-free survival (PFS) of 4.3months.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Colorectal cancer BRAF V600E mutation BRAF targeted therapy Biweekly cetuximab Genomic proflingTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
13 trang 38 0 0